search
Back to results

Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure (REaCH)

Primary Purpose

Congestive Heart Failure, Renal Insufficiency

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
furosemide and hypertonic saline solution
furosemide
Sponsored by
Aspirus Heart and Vascular Institute-Research and Education
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Congestive Heart Failure focused on measuring Congestive Heart Failure, Renal Insufficiency, Cardio-renal Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Uncompensated CHF
  • Framingham Criteria for HF

    • 2 Major or
    • 1 Major 2 minor

Major criteria:

  • Paroxysmal nocturnal dyspnea
  • Neck vein distention
  • Rales
  • Radiographic cardiomegaly (increasing heart size on chest radiography)
  • Acute pulmonary edema
  • S3 gallop
  • Increased central venous pressure (>16 cm H2O at right atrium)
  • Hepatojugular reflux
  • Weight loss > 4.5 kg in 5 days in response to treatment

Minor criteria:

  • Bilateral ankle edema
  • Nocturnal cough
  • Dyspnea on ordinary exertion
  • Hepatomegaly
  • Pleural effusion
  • Decrease in vital capacity by one third from maximum recorded
  • Tachycardia (heart rate>120 beats/min.)
  • No Ejection Fraction Inclusion Criteria
  • GFR £ 60 mL/min
  • GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American) (conventional units).
  • Informed consent

Exclusion Criteria:

  • Patients with Acute Coronary Syndrome
  • Post -op patients within 90 days of previous surgery
  • Patients currently on dialysis
  • Hospice patients
  • Patients < 18 years of age.

Sites / Locations

  • Aspirus Wausau Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Furosemide with Hypertonic Saline

Pulse Furosemide

Arm Description

Furosemide with 150 mL of 2.4% NaCl

80-160 mg furosemide (Given over 5 min IV twice a day)

Outcomes

Primary Outcome Measures

Renal function (GFR)

Secondary Outcome Measures

Diuretic response (defined as achievement of weight within 2% of previously determined dry body weight or reaching a clinically compensated state including return of functional level to prior NYHA class as determined by the primary treating physician)
Length of hospital stay
Readmission rate
Weight loss
BNP Levels
Hospitalization cost analysis

Full Information

First Posted
November 27, 2009
Last Updated
February 8, 2012
Sponsor
Aspirus Heart and Vascular Institute-Research and Education
Collaborators
Aspirus Wausau Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01028170
Brief Title
Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure
Acronym
REaCH
Official Title
Assessing the Renal Consequences and Functional Efficacy of Low Dose Hypertonic Saline Solution and Furosemide for the Treatment of Congestive Heart Failure in a Randomized, Double Blind, Prospective Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
January 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aspirus Heart and Vascular Institute-Research and Education
Collaborators
Aspirus Wausau Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare high dose furosemide in combination with low volume hypertonic saline solution (2.4%) with intermittent pulse dose furosemide in patients with pre treatment kidney function impairment. The hypothesis is that it will provide effective diuretic response and have a beneficial effect on preservation of renal function as compared to pulse furosemide in patients with pre-treatment renal impairment (GFR < 60 mL/min).
Detailed Description
Currently, congestive heart failure (CHF) is the fastest growing heart-related diagnosis in North America, with the chance of a person experiencing it during their lifetime around 20%. In patients with CHF, acute decompensation requiring hospitalizations are common. Patients with renal insufficiency are more susceptible to worsening of renal function or overt renal failure in relation to an episode of decompensated heart failure. Thus, there is a great need for treatment to help patients with renal dysfunction that can simultaneously protect them from further renal deterioration. Preliminary evidence indicates that hypertonic saline solution (HSS) combined with high dose loop diuretics may improve the prognosis for patients with CHF. In two separate studies, this treatment was found to alleviate symptoms of CHF, and significantly reduce hospital length of stay, as well as reduce morbidity and mortality subsequent to hospital stay. So far, available studies have demonstrated that renal function is not compromised when using HSS and high dose furosemide as a treatment for CHF. Preliminary data from our institution suggests that low volume HSS combined with high dose furosemide may be beneficial for patients with renal insufficiency. Hypothesis: High dose furosemide in combination with low volume HSS provides effective diuretic response and has a beneficial effect on preservation of renal function while in hospital as compared to pulse furosemide in patients with pre-treatment renal impairment (GFR < 60 mL/min).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congestive Heart Failure, Renal Insufficiency
Keywords
Congestive Heart Failure, Renal Insufficiency, Cardio-renal Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Furosemide with Hypertonic Saline
Arm Type
Experimental
Arm Description
Furosemide with 150 mL of 2.4% NaCl
Arm Title
Pulse Furosemide
Arm Type
Active Comparator
Arm Description
80-160 mg furosemide (Given over 5 min IV twice a day)
Intervention Type
Drug
Intervention Name(s)
furosemide and hypertonic saline solution
Intervention Description
250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
Intervention Type
Drug
Intervention Name(s)
furosemide
Intervention Description
80-160 mg furosemide (Given over 5 min IV twice a day)
Primary Outcome Measure Information:
Title
Renal function (GFR)
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Diuretic response (defined as achievement of weight within 2% of previously determined dry body weight or reaching a clinically compensated state including return of functional level to prior NYHA class as determined by the primary treating physician)
Time Frame
one week
Title
Length of hospital stay
Time Frame
30 days
Title
Readmission rate
Time Frame
6 months
Title
Weight loss
Time Frame
one week
Title
BNP Levels
Time Frame
discharge, 30 days and 6 months
Title
Hospitalization cost analysis
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Uncompensated CHF Framingham Criteria for HF 2 Major or 1 Major 2 minor Major criteria: Paroxysmal nocturnal dyspnea Neck vein distention Rales Radiographic cardiomegaly (increasing heart size on chest radiography) Acute pulmonary edema S3 gallop Increased central venous pressure (>16 cm H2O at right atrium) Hepatojugular reflux Weight loss > 4.5 kg in 5 days in response to treatment Minor criteria: Bilateral ankle edema Nocturnal cough Dyspnea on ordinary exertion Hepatomegaly Pleural effusion Decrease in vital capacity by one third from maximum recorded Tachycardia (heart rate>120 beats/min.) No Ejection Fraction Inclusion Criteria GFR £ 60 mL/min GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American) (conventional units). Informed consent Exclusion Criteria: Patients with Acute Coronary Syndrome Post -op patients within 90 days of previous surgery Patients currently on dialysis Hospice patients Patients < 18 years of age.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard S Engelmeier, MD
Organizational Affiliation
Aspirus Heart and Vascular Institute-Research and Education
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
German Larrain, MD
Organizational Affiliation
Aspirus Heart and Vascular Institute-Research and Education
Official's Role
Study Director
Facility Information:
Facility Name
Aspirus Wausau Hospital
City
Wausau
State/Province
Wisconsin
ZIP/Postal Code
54401
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
10973841
Citation
MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000 Sep 5;102(10):1126-31. doi: 10.1161/01.cir.102.10.1126.
Results Reference
background
PubMed Identifier
14760310
Citation
Lapman PG, Golduber GN, Le Jemtel TH. Heart failure treatment and renal function. Am Heart J. 2004 Feb;147(2):193-4. doi: 10.1016/j.ahj.2003.10.003. No abstract available.
Results Reference
background
PubMed Identifier
10915397
Citation
Paterna S, Parrinello G, Amato P, Dominguez L, Pinto A, Maniscalchi T, Cardinale A, Licata A, Amato V, Licata G, Di Pasquale P. Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure. Adv Ther. 1999 Sep-Oct;16(5):219-28.
Results Reference
background
PubMed Identifier
12660669
Citation
Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003 Mar;145(3):459-66. doi: 10.1067/mhj.2003.166.
Results Reference
background
PubMed Identifier
15963399
Citation
Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, Giammanco M, Sarullo FM, Licata G. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol. 2005 Jun 21;45(12):1997-2003. doi: 10.1016/j.jacc.2005.01.059.
Results Reference
background
Links:
URL
http://www.carefoundation.org
Description
Website for sponsoring organization

Learn more about this trial

Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure

We'll reach out to this number within 24 hrs